Vai ai contenuti. | Spostati sulla navigazione | Spostati sulla ricerca | Vai al menu | Contatti | Accessibilità

| Crea un account

Kotsafti, Andromachi (2008) Meccanismi estrinseci ed intrinseci del processo apoptotico nell'epatocarcinogenesi. [Tesi di dottorato]

Full text disponibile come:

[img]
Anteprima
Documento PDF
2705Kb

Abstract (inglese)

The mechanisms underlying the strict correlation between viral infection, cirrhosis and HCC development have been investigated in deep, but, despite this several aspects are still largely unknown or understood only in part. Hepatitis B and C viruses seem to be involved in neoplastic transformation through both direct and indirect mechanisms, due to inflammation process and the capacity of viral proteins in modulating the proliferation and the death of infected hepatocytes. Moreover it has been hypothesized that dysregulation of apoptotic process in infected cells could be a crucial step for the cronicity of infection, in the failure to antiviral treatment and in the neoplastic transformation.
Although apoptosis can be triggered by several different stimuli, apoptotic signalling within the cell is transduced mainly via two defined molecular pathways: the death receptor pathways, also called extrinsic pathway (Fas/FasL, TNF-?/TNF-R1-R2) and the mitochondrial pathway also called the intrinsic pathway (Bcl-2, Bax, Bad). Other plasma membrane receptors such as IL-1b and TGF-b1 and intrinsic mediators as BI-1 and NF-kB are involved in the apoptotic pathways. In this study mRNA expression of mediators of the extrinsic and intrinsic apoptotic process was evaluated. The liver biopsies and the surgical hepatic tissues obtained from patients with different degree of liver disease were used. mRNA transcripts were detected by gene amplifications techniques. on the basis of our results human hepatocytes cultures were performed. Primary hepatocytes were treated with TNF-a, Staurosporine and LY294002, protein-kinase inhibitors, in order to evaluate the activation and/or the inhibition of these mediators in the apoptotic process.
Aims
In the first part the study was performed in order to:
1) evaluate the mRNA expression of Fas/FasL, TNF-?, IL-1?, TGFß-1, Bcl-2, Bax, Bad, BI-1 and NF-kB in liver tissues from patients with different degrees of liver damage, from chronic hepatitis, to cirrhosis and hepatocellular carcinoma.
2) determine whether HCV and HBV infection modulates their expression
3) analyze the protein expression of the mediators identified by Western Blot, in liver tissues from patients with HCC
the second part included an "in vitro" study in order to:
4) culture primary human hepatocytes
5) evaluate the different apoptotic pathways in human hepatocytes after stimulation with:
a) TNF-?, mainly proinflammatory cytokine found in abundance in the inflammatory process relating to liver injury
b) Staurosporine (STS), a potent protein tyrosine/serine kinase inhibitor with an antiproliferative and anti-apoptotic activity in many tumoral cells
c) LY294002 synthetic inhibitor of PI3K (phosphoinositide 3-kinase)
Material and methods
We examined 62 patients: 39 with chronic hepatitis (CH), 7 with cirrhosis (CIRR), 13 with hepatocellular carcinoma HCC) and 3 controls (Contr). The Fas/FasL, IL-ß and TNF-? mRNAs were quantified by Semiquantitative RT-PCR, while the Bcl-2, Bax, Bad, BI-1, NF-kB and TGFß-1 mRNAs were quantified by quantitative Real Time PCR, using ß-actin as the housekeeping gene. The protein expression of NF-kB in tissues with HCC was analyzed by Western Blot.
Results
Tissues:
Fas/FasL mRNA expression:
Fas mRNA levels were significantly increased in CIRR when compared with HCC (p=0.026) while FasL mRNAs showed a statistically significant differences between CIRR and cirrhotic tissues surrounding tumours (PHCC) (p=0.018) or HCC (p=0.005).
IL-1ß mRNA expression:
PHCC tissues had higher IL-1b levels than either CH tissues (p<0,0001) or CIRR tissues (p=0,005).
TNF-? mRNA expression:
TNF-ß mRNAs were increased in CIRR tissues compared with PHCC (p=0,038) and HCC tissues (p=0,05).
TGFß-1 mRNA expression:
In CH tissues, TGFß-1 mRNA expression was significantly lower than in HCC (p=0,014) or PHCC tissues (p=0,028).
Bcl-2 mRNA expression:
Bcl-2 mRNA levels were statistically higher in PHCC when compared with normal liver tissues (p=0,026), with CH (p=0,004), and with CIRR (p=0,05).
BI-1 mRNA expression:
CH tissues expressed the highest BI-1 mRNA amount that was significantly higher when compared to cirrhotic tissues (p=0,033), cirrhotic tissues surrounding tumours (p<0,001) and HCC (p<0,001).
Bad mRNA expression:
Contr tissues showed the highest Bad transcript levels, which were statistically higher than in CH (p=0,006), PHCC (p=0,005), or HCC (p=0,002). CH coincided with higher Bad levels than in PHCC or HCC tissues (p=0,00006 and p=0,0007, respectively)
Bax mRNA expression:
No differences in Bax expression were observed.
NF-kB mRNA expression:
CONTR expressed the lowest NF-kB mRNA amount, significantly lower when compared with CH (p=0.05) and PHCC (p=0.05).
HBV HCV infection:
In CH, only TNF-?, IL-1ß and Bad mRNA expression were significantly different in HBV-related infection versus HCV-related infection.
Human hepatocytes:
TNF-? treatment:
Human hepatocytes incubated with TNF-? showed the highest levels of FasL (solo a 12h), IL-1ß(until 24h), TGFß-1 (24 e 48h), Bcl-2 (4h, 24h), Bad (24 and 48h) and NF-kB (8h) respect to unstimulated cells.
No differences in Fas, Bax, Bad (until 12h) , NF-kB (until 4h) e TGFß-1 (until 12h) mRNA levels were observed.
Staurosporine (STS) treatment:
In cells treated with STS, Bcl-2 mRNA expression until 48h of culture, was significantly lower than in unstimulated cells. No difference in TGFß-1, Bax, and NF-kB mRNAs levels were observed at the different time of incubation. While an increase in Bad mRNA at 12h and in BI-1 mRNA at 8 and 24h were observed.
LY294002 treatment:
LY294002 induce a strong inhibition of Bcl-2 mRNA (until 24h) in hepatocyte culture when compared with hepatocyte culture with medium alone. No difference in TGFß-1, Bax, and NF-kB mRNAs levels were observed while high levels of Bad mRNA at 12, 24 and 48h and of BI-1 from 8 to 24h of incubation were observed.
Pre-treatment with STS and LY294002 :
The pre-treatment of human hepatocytes for 1h with LY294002 and the following treatment with TNF-? inhibits the Bcl-2 mRNA expression until 48h when compared with cell treated with TNF-? without the pre-treatment. This inhibition was completely resolved after 48h of incubation.
In cells pretreated with LY294002 respect to the cells treated with TNF-? alone, were observed the highest levels of Bax after 4h, Bad after 24h e BI-1 after 24h of incubation.
No difference in TGFß-1 and NF-kB mRNAs expression were observed
In the cells pre-treated with STS only the BI-1 transcript levels were increased until 24h.
TISSUES
Fas/FasL system expression is upregulated in chronically-damaged livers while the onset of cancer is associated with a shut-down of this system in HCC, as a defense mechanisms adopted by HCC against the immune system.
High levels of IL-1ß mRNA transcripts observed in cirrhotic tissues surrounding tumours, may be the result of an increased activation of lymphocytes o monocytes in the liver.
Contrary, the low expression of TNF-? mRNA transcripts in cirrhotic tissues surrounding tumours and HCC may be the result of loss function of Kupffer cells, one of the main sources of production of TNF-? in the liver.
The Bcl-2 hyperexpression observed in cirrhotic peritumoral tissues seems to play an important part in regulating cell survival in damaged liver cells, which may contribute to the persistence of HBV or HCV and thus activate cell proliferation and cell transformation.
The upregulation of the Bad-induced pro-apoptotic pathway in CH seems to be more relevant in controlling apoptosis in liver tissues with HBV infection suggesting an important role of the proteins of HBV particularly in early liver diseases.
Moreover the BI-1 expression decrease correlates closely with the progression of liver damage from CH to cirrhosis and HCC and indicate a role of BI-1 as regulator of apoptosis in early diseases. The high BI-1 mRNA levels observed in CH may provide protection against apoptosis of liver cells virus infected, on the other hand the down regulation of BI-1 observed in HCC tissues seems to favour the hapatocellular carcinogenesis.
The persistently elevated levels of NF-kB in all stage of liver diseases, seems to depends on a chronic inflammatory with an consequently increased risk of hepatic fibrosis and of an HCC milieu.
The different pattern of IL-1ß, TNF-? and Bad expression in HCV- and HBV-related liver disease points to a different modulation of the immune response on the one hand, and to a different apoptotic activation pathways on the other.
HUMAN HEPATOCYTES
IL-1ß and TNF-? are proinflammatory cytokines always secreted during inflammation.
The high IL-1ß mRNA transcripts induced by TNF-? stimulation in primary human hepatocytes suggest that the presence of TNF-? in the hepatic microenvironment contributes to the increase in IL-1ß with a consequent intensification of inflammatory, proliferative and regenerative processes.
No difference in Fas/FasL mRNAs expression was observed after TNF-? treatment, suggesting that the expression of these mediators was not modulated by the extracellular TNF-?  factor in our experimental conditions.
Bcl-2 is an antiapoptotic member of the intrinsic Bcl-2 family and its activation by TNF-? might explain the resistance to apoptotic process induced by TNF-? also observed in mouse and rat hepatocyte cultures.
Pre-treatment and treatment with STS, LY924002 and TNF-? reduce the Bcl-2 transcript levels by comparison with the levels obtained from cells treated with TNF-? alone. These effects were particularly evident using LY924002. STS is considered a scarcely-selective kinase inhibitor known for its toxicity, while LY924002 represents a highly specific PI3K inhibitor.
Bax and Bad are pro-apoptotic members of the BCl-2 family.
TNF-?, STS and LY294002 had no effect on Bax expression in human hepatocytes compared with hepatocytes incubated with medium alone, whereas Bad mRNA levels increased after stimulation with TNF-? STS and LY294002, particularly after 12 to 48 hours of incubation.
Costimulation with LY294002 and TNF-? increases the Bad mRNAs after 24h and 48h of incubation. So, when the antiapoptotic pathway (Bcl-2) was inhibited in primary human hepatocytes, members of the apoptotic pathway (Bad and Bax) were activated.






Statistiche Download - Aggiungi a RefWorks
Tipo di EPrint:Tesi di dottorato
Relatore:Bortolami, Marina
Dottorato (corsi e scuole):Ciclo 20 > Scuole per il 20simo ciclo > BIOLOGIA E MEDICINA DELLA RIGENERAZIONE > SCIENZE EPATOLOGICHE E GASTROENTEROLOGICHE
Data di deposito della tesi:31 Gennaio 2008
Anno di Pubblicazione:31 Gennaio 2008
Parole chiave (italiano / inglese):APOPTOSI, mRNA, Fas/FasL, TNF-alpha, IL-1beta, Bcl-2, Bax, Bad, BI-1, NF-kB, TGFbeta-1, epatocarcinogenesi, HBV, HCV
Settori scientifico-disciplinari MIUR:Area 06 - Scienze mediche > MED/12 Gastroenterologia
Struttura di riferimento:Dipartimenti > Dipartimento di Scienze Chirurgiche Gastroenterologiche "Pier Giuseppe Cevese"
Codice ID:915
Depositato il:28 Ott 2008
Simple Metadata
Full Metadata
EndNote Format

Bibliografia

I riferimenti della bibliografia possono essere cercati con Cerca la citazione di AIRE, copiando il titolo dell'articolo (o del libro) e la rivista (se presente) nei campi appositi di "Cerca la Citazione di AIRE".
Le url contenute in alcuni riferimenti sono raggiungibili cliccando sul link alla fine della citazione (Vai!) e tramite Google (Ricerca con Google). Il risultato dipende dalla formattazione della citazione.

1. Steller H : Mechanisms and Genes of Cellular Suicide. Science 1995; 267: 1445-1456. Cerca con Google

2. Williams GT : Programmed Cell Death: Apoptosis and Oncogenesis. Cell 1991; 65: 1097-1098. Science 1995; 267: 1456-1462. Cerca con Google

3. Benedetti A, Marucci L: The Significance of apoptosis in the liver. Liver 1999; 19: 453-463. Cerca con Google

4. Tartaglia LA, Ayres TM, Wong GHW, Goeddel DV. A novel domain within the 55 kd TNF receptor signals cell death. Cell 1993 Sep 10; 74(5): 845-53. Cerca con Google

5. Inazawa J, Itoh N, Abe T, Nagata S. Assignment of the human Fas antigen gene (Fas) to 10q24.1. Genomics 1992 Nov; 14(3): 821-2. Cerca con Google

6. Behrmann I, Walczak H, Krammer PH. Structure of the human APO-1 gene. Eur J Immunol. 1994; 24(12): 3057-62. Cerca con Google

7. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, Debatin Km, Krammer PH. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989 Jul 21; 245(4915): 301-5. Cerca con Google

8. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989 May 1; 169(5): 1747-56. Cerca con Google

9. Takahashi T, Tanaka M, Inazawa J, Abe T, Suda T, Nagata S. Human Fas ligand: gene structure, chromosomal location and species specificity. Int.Immunol. 1994; 6: 15467. Cerca con Google

10. Suda T, Okazaki T, Naito Y, Yokota T, Arai N, Ozaki S, Nakao K, Nagata S. Expression of the Fas ligand in cells of T cell lineage. Int.Immunol. 1995 April 15; 154(8): 3806-13. Cerca con Google

11. Rouvier E, Luciani MF, Golstein P, Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity. J.Exp.Med 1993 Jan 1; 177(1): 195-200. Cerca con Google

12. Suda T, Nagata S. Purification and characterization of the Fas-ligand that induces apoptosis. J.Exp.Med. 1994 Mar 1; 179(3): 873-9. Cerca con Google

13. Pinkoski MJ, Brunner T, Green DR, Lin T. Fas and Fas ligand in gut and liver. Am J Physiol Gastrointest Liver Physiol 2000; 278: G354-G366. Cerca con Google

14. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue cinetics. Br J Cancer 1972; 26: 239-257. Cerca con Google

15. Old LJ. Tumor necrosis factor (TNF). Science 1985 Nov 8; 230(4726): 630-2. Cerca con Google

16. Muller U, Jongeneel CV, Nedospasov SA. Tumor necrosis factor and lymphotoxin genes map closet o H-2D in the mouse major histocombatibility complex. Nature 1987; 325: 265-267. Cerca con Google

17. Nedwin GE, Naylor SL, Sakaguchi AY, Smith D, Jarrett-Nedwin, Pennica D, Goeddel D, Gray Cerca con Google

18. Bazzoni F, Beutker B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996; 334: 1717-1725. Cerca con Google

19. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104:487-501. Cerca con Google

20. Osawa Y, Banno Y, Nagaki M, Brenner DA, Naiki T, Nozawa Y. TNF-a-induced sphingosine 1-phosphate inhibits apoptosis through a phosphatidylinositol 3-kinase/Akt pathway in human hepatocytes. J Immunol 2001; 167: 173-80. Cerca con Google

21. Bemelmans MH, van Tits LJ, Buurman WA. Tumor necrosis factor: function, release and clearance. Crit Rev Immunol 1996; 16: 1-11. Cerca con Google

22. Tartaglia LA, Goeddel DV. Two TNF receptors. Immunol Today 1992; 13: 151-153. Cerca con Google

23. Aggarwal BB. Signaling pathways of the TNF superfamily; a double-edged sword. Nat Rev Immunol 2003: 3: 745-756. Cerca con Google

24. Ashkenazi A, Dixit VM. Death receptors: signaaling and modulation. Science 1998; 281: 1305-1308. Cerca con Google

25. Baker SJ, Reddy EP. Modulation of life and death by the TNF receptor superfamily. Oncogene 1998; 17: 3261-3270. Cerca con Google

26. Muppidi JR, Tschopp J, Siegel RM. Life and death decisions; secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity 2004; 21: 461-465. Cerca con Google

27. Takada H, Chen NJ, Mirtsos C. Role of SODD in regulation of tumor necrosis factor responses. Mol Cell Biol 2003; 23: 4026-4033. Cerca con Google

28. Rath PC, Aggarwal BB. TNF-induced signalling in apoptosis. J Clin Immunol 1999; 19: 350-364. Cerca con Google

29. Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene 2003; 22: 8543-8567. Cerca con Google

30. Devin A, Cook A, Lin Y. The distinct roles of TRAF2 and RIP in IKK activation by TNFR-1: TRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation. Immunity 2000; 12: 419-429. Cerca con Google

31. Adams J.M, Cory S: The Bcl-2 protein Family: Arbiters of Cell Survival. Science 1998; 281: 1322-1326. Cerca con Google

32. Chao D.T, Korsmeyer S.J, Bcl-2 family: regulators of cell death. Annu. Rev. Immunol. 1998; 16: 395-419. Cerca con Google

33. Cory S, Adams J. M: The Bcl-2 Family: Regulators of the cellular life or death switch. Nat Rev Cancer 2002; 2: 647-656. Cerca con Google

34. Nguyen M., Millar D.G, Yong V.W, Korsmeyer S.J, Shore G.C: Targeting of Bcl-2 to the mitochondrial outer membrane by a COOH-terminal signal anchor sequence. J. Biol. Chem 1993; 268: 25265-25268. Cerca con Google

35. Puthalakayh H., Strasser A: Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ 2002; 9: 505-512. Cerca con Google

36. Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG, Youle RJ: Movement of Bax from the citosol to mitochondria during apoptosis. J Cell Biol 1997; 139: 1281-1292. Cerca con Google

37. Gross A, Jockel J, Wei MC, Korsmeyer SJ: Enforced dimerization of Bax results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J 1998; 17: 3878-3885. Cerca con Google

38. Antonsson B, Montessuit S, Sanchez B, Martinou JC : Bax is present as a high molecular weight oligomer/ complex in the mitochondrial membrane of apoptotic cells. J Biol Chem 2001; 276: 11615-11623. Cerca con Google

39. Chen M, Wang J: Initiator caspases in apoptosis signalling pathways. Apoptosis 2002; 7: 313-319. Cerca con Google

40. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, Displaces Bax and promotes cell death. Cell 1995 Jan 1995; 80: 285-291. Cerca con Google

41. Adachi B, Zhang Y.B, Imai K. Mutation of BAD within the BH3 domain impairs its phosphorylation-mediated regulation. FEBS Lett, 2003; 551: 147-152. Cerca con Google

42. Tan Y, Ruan H, Demeter MF, Comb MJ. p90(RSK) blocks bad-mediated cell death via a protein kinase C-dependent pathway. J. Biol. Chem, 1999; 274: 34859-34867. Cerca con Google

43. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91:231-241. Cerca con Google

44. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science, 1997; 278: 687-689. Cerca con Google

45. Virdee K, Parone PA, Tolkovsky AM. Phosphorylation of the pro-apoptotic protein BAD on serine 155, a novel site, contributes to cell survival. Curr. Biol 2000; 10: 1151-1154. Cerca con Google

46. Wang HG, Rapp UR, Reed JC. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 1996; 87: 629-638. Cerca con Google

47. Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc. Natl. Acad. Sci. Usa 2001; 98: 9666-9670. Cerca con Google

48. Bergmann A. Survival signalling goes Bad. Dev. Cell 2002; 3: 607-608. Cerca con Google

49. Borner C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol. Immunol 2003; 39: 615-647. Cerca con Google

50. Xu, Q., Reed, J C: Bax inhibitor-1, a mammalian apoptosis suppressor identified by functional screening in yeast. Mol Cell 1998, 1 (3): 337-46. Cerca con Google

51. Chae HJ, Ke N, Kim HR, Chen S, Godgik A, Dickman M, Reed JC: Evolutionarily conserved cytoprotection provided by Bax Inhibitor-1 homologs from animals, plants, and yeast. Gene 2003; 323 : 101-113. Cerca con Google

52. Bolduc N, Ouellet M, Pitre F, Brisson LF. Molecular characterization of two plant BI-1 homologues which suppress Bax-induces apoptosis in human 293 cells. Planta 2003; 216 (3): 377-86. Cerca con Google

53. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991 Apr 15;77(8):1627-52. Cerca con Google

54. Arend WP. Interleukin-1 receptor antagonist. Adv Immunol. 1993; 54:167-227 Cerca con Google

55. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996 Mar 15; 87(6): 2095-147 Cerca con Google

56. Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y, Voronov E. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 2006 Sep; 25(3): 387-408 Cerca con Google

57. Dinarello CA, Moldawer LL. Proinfiammatory and anti-infiammatory cytokines in rheumatoid arthritis. A primer for clinicians, 2nd edn, pp.1-15. Amgen, Inc, Thousand Oaks, CA. Cerca con Google

58. Sims JE, Giri JG, Dower SK. The two interleukin-1 receptors play different roles in IL-1 actions. Clin Immunol Immunopathol. 1994 Jul; 72(1): 9-14. Cerca con Google

59. Yan Z, Deng X, Friedman E. Oncogenic Ki-ras confers a more aggressive colon cancer phenotype through modification of transforming growth factor-beta receptor III. J Biol Chem 2001; 276: 1555-1563. Cerca con Google

60. Desruisseau S, Ghazarossian-Ragni E, Chinot O. Divergent effect of TGFbeta1 on growth and proteolytic modulation of human prostatic-cancer cell lines. Int J Cancer 1996; 66: 796-801. Cerca con Google

61. Perry RR, Kang Y, Greaves BR. Relationship between tamoxifen-induced transforming growth factor beta 1 expression, cytostasis and apoptosis in human breast cancer cells. Br J Cancer 1995; 72: 1441-1446. Cerca con Google

62. Ananth S, Knebelmann B, Gruning W. Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma. Cancer Res 1999; 59: 2210-2216. Cerca con Google

63. Torre-Amione G, Beauchamp RD, Koeppen H. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 1990; 87: 1486-1490. Cerca con Google

64. Roberts AB, Sporn MB. In Peptide Growth Factors and their Receptors-Handbook of Experimental Pharmacology (eds Sporn, MB & Roberts AB). Springer, Heidelberg 1990; 419-472. Cerca con Google

65. Massaguè J. TGF-b signal transduction. Annu Rev Biochem 1998; 67: 753-791. Rewiew Cerca con Google

66. Gentry LE, Lioubin MN, Purchio AF, Marquardt H. Molecular events in the processing of recombinant type 1 pre-pro-trans-forming growth factor ß to the mature polypeptide. Mol Cell Biol 1988; 8: 4162-4168. Cerca con Google

67. Gleizes PE, Beavis RC, Mazzieri R, Shen B, Rifkin DB. Identification and characterization of an eight-custeine repeat of the latent transforming growth factor-beta binding protein-1 that mediates bonding to the latent transforming growth factor-beta 1. J Biol Chem 1996; 271: 29891-29896. Cerca con Google

68. Saharinen J, Taipale J, Keski-Oja J. Association of the small latent transforming growth factor-beta with an eight cysteine repeat of this binding protein LTBP-1. EMBO J 1996; 15: 245-253. Cerca con Google

69. Massague J. TGF-beta signal transduction. Annu. Rev. Biochem 1998; 67: 753-791. Cerca con Google

70. Tsuchida K, Lewis KA, Mathews LS, Vale WW. Molecular characterization of rat trasforming growth factor-beta type II receptor. Biochem Biophys Res Commun 1993; 191(3): 790-795. Cerca con Google

71. Takumi T, Moustakas A, Lin HY, Lodish HF. Molecular characterization of a type I serine-threonine kinase receptor for TGF-beta and activin in the rat pituitary tumor cell line GH3. Exp Cell Res 1995; 216(1): 208-214. Cerca con Google

72. Attisano L, Wrana JL, Cheifetz s, Massague J. Novel activin receptors: distinct genes and alternative mRNA splicing generate a repertoire of serine/threonine kinase receptors. Cell 1992; 68(1): 97-108. Cerca con Google

73. Shi Y, Massague J. Mecchanisms of TGF-ß signaling from cell membrane to the nucleus. Cell 2003; 113: 685-700. Cerca con Google

74Attisano L, Wrana JL. Signal transduction by TGF-ß superfamily. Science 2002; 296: 1646-1647. Cerca con Google

75. Piek E, Heldin CH, Ten Dijke P. Specificity, diversity, and regulation in TGF-ïß superfamily signaling. FASEB J 1999; 132105-2124. Cerca con Google

76. Karin M. The beginning of the end: IkB kinase (IKK) and NF-kB activation. J Biol Chem 1999; 274: 27399-27342. Cerca con Google

77. Barnes BJ, Karin M. Nuclear factor-kB, a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-1071. Cerca con Google

78. Chen F, Castranova V, Shi X, Demers LM. New insights into the role of nuclear factor-kB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 1999; 45: 7-17. Cerca con Google

79. Thorgeirsson S, Teramoto T, Factor V. Dysregulation of Apoptosis in Hepatocellular Carcinoma. Seminars in Liver Disease 1998; 18 (2): 115-122. Cerca con Google

80. Shih WL, Kuo ML, Chuang SE, Cheng AL, Doong SL. Hepatitis B virus X protein inhibits transforming growth factor-beta -induced apoptosis through the activation of phosphatidylinositol 3-kinase pathway. J Biol Chem. 2000 Aug 18; 275 (33):25858-64. Cerca con Google

81. Pan J, Duan LX, Sun BS, Feitelson MA. Hepatitis B virus X protein protects against anti-Fas-mediated apoptosis in human liver cells by inducing NF-kappa B. J Gen Virol. 2001 Jan; 82 (Pt 1): 171-82. Cerca con Google

82. Diao J, Khine AA, Sarangi F, Hsu E, Iorio C, Tibbles LA, Woodgett JR, Penninger J, Richardson CD. X protein of hepatitis B virus inhibits Fas-mediated apoptosis and is associated with up-regulation of the SAPK/JNK pathway. J Biol Chem. 2001 Mar 16; 276(11):8328-40 Cerca con Google

83. Chen GG, Lai PB, Chan PK, Chak EC, Yip JH, Ho RL, Leung BC, Lau WY. Decreased expression of Bid in human hepatocellular carcinoma is related to hepatitis B virus X protein. Eur J Cancer. 2001 Sep; 37(13):1695-702. Cerca con Google

84. Shin EC, Shin JS, Park JH, Kim H, Kim SJ: Expression of Fas-ligand in human epatoma cell lines: role of hepatitis B virus X (HBX) in induction of Fas ligand. Int J Cancer 1999; 82 (4): 587-91. Cerca con Google

85. Ray RB, Lagging LM, Meyer K, Steele R, Ray R: Transcriptional regulation of cellular and viral promoters by the hepatitis C virus core protein. Virus Res 1995; 37: 209-220. Cerca con Google

86. Terradillos O, de La Coste A, Pollicino T, Neuveut C, Sitterlin D, Lecoeur H, Gougeon ML, Kahn A, Buendia MA. The hepatitis B virus X protein abrogates Bcl-2-mediated protection against Fas apoptosis in the liver. Oncogene 2002 Jan 17; 21(3): 377-86 Cerca con Google

87. Zhang SJ, Chen HY, Chen ZX, Wang XZ. Possible mechanism for hepatitis B virus X gene to induce apoptosis of hepatocytes. World J Gastroenterol 2005 Jul 28; 11(28): 4351-6. Cerca con Google

88. Kim WH, Hong F, Jaruga B, Zhang ZS, Fan SJ, Liang TJ, Gao B. Hepatitis B virus X protein sensitizes primary mouse hepatocytes to ethanol- and TNF-alpha-induced apoptosis by a caspase-3-dependent mechanism. Cell Mol Immunol 2005 Feb; 2(1):40-8. Cerca con Google

89. Miao J, Chen GG, Chun SY, Lai PP. Hepatitis B virus X protein induces apoptosis in hepatoma cells through inhibiting Bcl-xL expression. Cancer Lett 2006 May 8; 236(1):115-24. Cerca con Google

90. Zhang X, Dong N, Yin L, Cai N, Ma H, You J, Zhang H, Wang H, He R, Ye L. Hepatitis B virus X protein upregulates survivin expression in hepatoma tissues. J Med Virol 2005 Nov; 77(3): 374-81. Cerca con Google

91. Ruggieri A, Harada T, Matsuura Y, Miyamura T. Sensitization to Fas-mediated apoptosis by hepatitis C virus core protein. Virology 1997 Mar 3; 229(1): 68-76. Cerca con Google

92. Zhu N, Khoshnan A, Schneider R, Matsumoto M, Dennert G, Ware C, Lai MM. Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. J Virol 1998 May; 72(5): 3691-7. Cerca con Google

93. Joo M, Hahn YS, Kwon M, Sadikot RT, Blackwell TS, Christman JW. Hepatitis C virus core protein suppresses NF-kappaB activation and cyclooxygenase-2 expression by direct interaction with IkappaB kinase beta. J Virol 2005 Jun; 79(12): 7648-57. Cerca con Google

94. Majumder M, Ghosh AK, Steele R, Zhou XY, Phillips NJ, Ray R, ray RB: Hepatitis C virus NS5A protein impairs TNF-mediated hepatic apoptosis, but not by anti-Fas antibody in transgenic mice. Virology 2002; 294: 94-105. Cerca con Google

95. Otsuka M, Kato N, Taniguchi H, Yoshida H, Goto T, Shiratori Y, Omata M. Hepatitis C virus core protein inhibits apoptosis via enhanced Bcl-xL expression. Virology 2002 Apr 25; 296(1): 84-93. Cerca con Google

96. Pavio N, Battaglia S, Boucreux D, Arnulf B, Sobesky R, Hermine O, Brechot C. Hepatitis C virus core variants isolated from liver tumor but not from adjacent non-tumor tissue interact with Smad3 and inhibit the TGF-beta pathway. Oncogene 2005 Sep 8; 24(40): 6119-32. Cerca con Google

97. Tai DI, Tsai SL, Chen YM, Chuang YL, Peng CY, Sheen IS, Yeh CT, Chang KS, Huang SN, Kuo GC, Liaw YF. Activation of nuclear factor kappaB in hepatitis C virus infection: implications for pathogenesis and hepatocarcinogenesis. Hepatology 2000 Mar; 31(3): 656-64. Cerca con Google

98. Ray RB, Steele R, Basu A, Meyer K, Majumder M, Ghosh AK, Ray R. Distinct functional role of Hepatitis C virus core protein on NF-kappaB regulation is linked to genomic variation. Virus Res 2002 Jul; 87(1): 21-9. Cerca con Google

99. Kurose I, Higuchi H, Miura S, Saito H, Watanabe N, Hokari R, Hirokawa M, Takaishi M, Zeki S, Nakamura T, Ebinuma H, Kato S, Ishii H. Oxidative stress-mediated apoptosis of hepatocytes exposed to acute ethanol intoxication. Hepatology 1997 Feb; 25(2): 368-78. Cerca con Google

100. French SW, Wong K, Jui L, Albano E, Hagbjork AL, Ingelman-Sundberg M. Effect of ethanol on cytochrome P450 2E1 (CYP2E1), lipid peroxidation, and serum protein adduct formation in relation to liver pathology pathogenesis. Exp Mol Pathol 1993 Feb; 58(1): 61-75. Cerca con Google

101. Natori S, Rust C, Stadheim LM, Srinivasan A, Burgart LJ, Gores GJ. Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis. J Hepatol 2001 Feb; 34(2): 248-53. Cerca con Google

102. Tagami A, Ohnishi H, Moriwaki H, Phillips M, Hughes RD. Fas-mediated apoptosis in acute alcoholic hepatitis. Hepatogastroenterology 2003 Mar-Apr; 50(50): 443-8. Cerca con Google

103. Hug H, Strand S, Grambihler A, Galle J, Hack V, Stremmel W, Krammer PH, Galle PR. Reactive oxygen intermediates are involved in the induction of CD95 ligand mRNA expression by cytostatic drugs in hepatoma cells. J Biol Chem. 1997 Nov 7; 272(45): 28191-3. Cerca con Google

104. Chan H, Bartos DP, Owen-Schaub LB. Activation-dependent transcriptional regulation of the human Fas promoter requires NF-kappaB p50-p65 recruitment. Mol Cell Biol 1999 Mar; 19(3): 2098-108. Cerca con Google

105. McClain C, Hill D, Schmidt J, Diehl AM. Cytokines and alcoholic liver disease. Semin Liver Dis 1993 May; 13(2): 170-82. Cerca con Google

106. Costelli P, Aoki P, Zingaro B, Carbò N, Reffo P, Lopez-Soriano FJ, Bonelli G, Argilés JM, Baccino FM. Mice lacking TNFalpha receptors 1 and 2 are resistant to death and fulminant liver injury induced by agonistic anti-Fas antibody. Cell Death Differ 2003 Sep;10(9): 997-1004. Cerca con Google

107. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, Gores GJ. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003 Aug; 125(2): 437-43. Cerca con Google

108. Feldstein AE, Canbay A, Guicciardi ME, Higuchi H, Bronk SF, Gores GJ. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol 2003 Dec; 39(6): 978-83. Cerca con Google

109. Nehra V, Angulo P, Buchman AL, Lindor KD. Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis. Dig Dis Sci 2001 Nov; 46(11): 2347-52. Cerca con Google

110. Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, Rydzewski R, Burgart LJ, Gores GJ. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004 Jul; 40(1): 185-94. Cerca con Google

111. Faubion WA, Guicciardi ME, Miyoshi H, Bronk SF, Roberts PJ, Svingen PA, Kaufmann SH, Gores GJ. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J Clin Invest 1999 Jan; 103(1): 137-45. Cerca con Google

112. Higuchi H, Bronk SF, Takikawa Y, Werneburg N, Takimoto R, El-Deiry W, Gores GJ. The bile acid glycochenodeoxycholate induces trail-receptor 2/DR5 expression and apoptosis. J Biol Chem 2001 Oct 19; 276(42): 38610-8 Cerca con Google

113. Canbay A, Feldstein AE, Higuchi H, Werneburg N, Grambihler A, Bronk SF, Gores GJ. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 2003 Nov; 38(5): 1188-98. Cerca con Google

114. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991 Jul 5; 253(5015): 49-53. Cerca con Google

115. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993 Oct 28; 329(18): 1318-27. Cerca con Google

116. Liu X, Yue P, Khuri FR, Sun SY. p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res 2004 Aug 1; 64(15): 5078-83. Cerca con Google

117. Lin P, Bush JA, Cheung KJ Jr, Li G. Tissue-specific regulation of Fas/APO-1/CD95 expression by p53. Int J Oncol 2002 Aug; 21(2): 261-4. Cerca con Google

118. Müller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, Friedman SL, Galle PR, Stremmel W, Oren M, Krammer PH. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 1998 Dec 7; 188(11): 2033-45. Cerca con Google

119. Hahne M, Rimoldi D, Schröter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996 Nov 22; 274(5291): 1363-6 Cerca con Google

120. Strand S, Hofmann WJ, Hug H, Müller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion? Nat Med 1996 Dec; 2(12): 1361-6. Cerca con Google

121. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995 Nov 17; 270(5239):1189-92. Cerca con Google

122. Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. Mechanisms of hepatotoxicity. Toxicol Sci 2002 Feb; 65(2): 166-76. Cerca con Google

123. Edmonson HA, Steiner PE: Primary carcinoma of the liver: A study of 100 cases among 48900 necropsies. Cancer 1954; 7: 462-503. Cerca con Google

124. Ishak k, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmeet V, Korb G, MacSween RNM, Phillips MJ, Portmann BG, Poulsen H, Scheuer PJ, Schmid M, Thaler H. Histological grading and staging of chronic hepatitis. J Hepatology 1995; 22: 696-699. Cerca con Google

125. Chomczynski P, Sacchi N: Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. AnalBiochem 1987; 162: 156-159. Cerca con Google

126. Maggi A: Biologia molecolare manuale pratico. Ed. Masson 1990. Cerca con Google

127. SA Bustin: Absolute quantification of mRNA using Real-Time reverse transcription polymerase chain reaction assays. Journal of Molecular Endocrinology (2000) 25, 169-193. Cerca con Google

128. reeman WM, Walker SJ, Vrana KE: Quantitative PCR: Pitfall end potential. Biotechniques 1999; 26(1): 124-125 Cerca con Google

129. Al-Robaiy S, Eschrich K: Rapid competitive PCR using melting curve analysis for DNA quantification. Biotechniques 2001 Dec; 31(6): 1382-6,1388. Cerca con Google

130. Ririe KM, Rasmussen RP & Wittwer CT. Product differentiation by analysis of Dna melting curves during the polymerase chain reaction. Analytical Biochemistry 1997; 245: 154-160. Cerca con Google

131. Yano H, Fukuda K, Karamaki M, Momosaki S, Ogasawara S, Higaki K, Kojiro M. Expression of Fas and anti-Fas-mediated apoptosis in human hepatocellular carcinomacell line. J Hepatology 1996; 25: 454-464. Cerca con Google

132. bertoletti A, Ferrari C. Kinetics of the immune response during HBV and HCV infection. Hepatology 2003; 38(1): 4-13. Cerca con Google

133. Iken K, Huang L, Bekele H, Schmidt EV, Koziel Mj. Apoptosis of activated CD4+ and CD8+ T cell is enhanced by co-culture with the hepatocytes expressing hepatitis C virus (HCV) sructural proteins through FasL induction. Virology 2006; 346:363-372. Cerca con Google

134. Chang KM, Thimme R, Melpolder JJ. Differential CD4+ and CD8+ T cell responsiveness in hepatitic C virus infection. Hepatology 2001; 33: 267-276. Cerca con Google

135. Bossu P, Del Grosso E, Cesaroni MP, Maurizi G, Balestro N, Stoppaccioaro A, del Giudice E, Ruggiero P, Boraschi D. Balance between autocrine interleukin-1 beta and caspases defines life versus death of polymorphonuclear cells. Eur Cytokine Netw 2001; 12(1): 177-186. Cerca con Google

136. Majumber M, Ghoh AK, Steele R, Zhou XY, Philips NJ, Ray R, Ray RB. Hepatitis C virus NS5A protein impairs TNF-mediated hepatic apoptosis, but not by anti-Fas antibody in transgenic mice. Virology 2002; 294: 94-105. Cerca con Google

137. Otsuka M, Kato N, Taniguchi H, Yoshida H, Goto T, Shiratori Y, Omata M. Hepatitis C virus core protein inhibits apoptosis via enhanced Bcl-Xl expresion. Virology 2002 Apr 25; 296(1): 84-93. Cerca con Google

138. Zhu N, Ware CF, Lai MM,. Hepatitis C virus core protein enhances FADD-mediated apoptosis and suppresses TRADD signaling of tumor necrosis factor receptor. Virology 2001 May 10; 283(2): 178-187. Cerca con Google

139. Bortolami M, Venturi C, Giacomelli L, Scalerta R, Bacchetti S, Marino F, Floreani A, Lise M, Naccarato R, Farinati F. Cytokine, infiltrating macrophages and T cell-mediated response to development of primary and secondary human liver cancer. Dig Liver Dis 2002; 34: 794-801. Cerca con Google

140. Souto EO, Miyoshi H, Dubois RN, Gores GJ. Kupffer cell-derived cyclo-oxygenase-2 regulates hepatocyte Bcl-2 expression in choledoco-venous fistula rats. Am J Physiol Gastrointest Liver Physiol 2001; 280: G805-G811. Cerca con Google

141. Kojima Y, Suzuki S, Tsuchiya Y, Konno H, Baba S, Nakamura S. Regulation of pro-infiammatory and anti-infiammatory cytokine rsponses by kupffer cells in endotoxin-enhanced reperfusion injury after total hepatic ischemia. Transpl Int 2003; 16: 231-240. Cerca con Google

142. Wheeler MD, Kono H, Yin M, Nakagami M, Uesugi T, Arteel GE, Gabele E. The role of Kupffer cell oxidant production in early ethanol induced liver disease. Free radic Biol Med 2001; 31: 1544-1549. Cerca con Google

143. Sun Z, Wada T, Maemura K, Uchikura K, Hoshino S, Diehl AM, Klein AS. Hepatic allograft-derived Kupffer cells regulate T cell response in rats. Liver Transpl 2003; 9: 489-497. Cerca con Google

144. Fischer R, Cariers A, Reinehr R, Haussinger D. Cspase 9-dependent killing of hepatic stellate cells by activated Kupffer cells. Gastroenterology 2002; 123: 845-861. Cerca con Google

145. Adachi Y, Bradford BU, Gao W, Bojes HK, Thurman RG. Inactivation of Kupffer cells prevents early alcohol-induced liver injury. Hepatology 1994; 20: 453-460. Cerca con Google

146. Canbay A, feldstein AE, Higuchi H. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 2003; 38: 1188-1198. Cerca con Google

147. Dong ZZ, Yao DF, Zou L, Yao M, Qiu LW, Wu XH, Wu W. An evaluation of trasforming growth factor-beta1 in diagnosing hepatocellular carcinoma and metastasis. Zhonghua Gan Zang Bing Za Zhi 2007; 15(7): 503-508. Cerca con Google

148. Moses HL, Yang EY, Pietenpol JA. TGF-ß stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 1990; 63: 245-247. Cerca con Google

149. Zavadil J, Bottinger EP. TGF-ß and pithelial-to-mesenchimal transitions. Oncogene 2005; 24: 5764-5774. Cerca con Google

150. Heldin CH, Miyazono K, ten Dijke P. TGF-ß signaling from cell membrane to nuclleus through SMAD proteins. Nature 1997; 390: 465-471. Cerca con Google

151. Wrana JL. Crossing Smads. Sci STKE 2000; 23:RE1. Cerca con Google

152. Saika S, Kono-Saika S, Ohnishi Y, Sato M, Muragaki Y, Ooshima A. Smad3 signaling is required for epithelial-mesenchymal transition of lens epithelium after injury. Am J Pathol 2004; 164: 651-663. Cerca con Google

153. Matsuzaki K. Smad3 phosphoisoform-mediated signaling during sporadic human colorectal carcinogenesis. Histol Histopathol 2006; 21: 645-662. Cerca con Google

154. Yoshida K, Matsuzaki K, Mori S, Tahashi Y, Yamagata H, Furukawa F. Trasforming growth factor-ß and platelet-derived growth factor signal via c-Jun N-terminal kinase-dependent Smad2/3 phosphorylation in rat hepatic stellate cells after acute liver injury. Am J Pathol 2005; 166: 1029-1039. Cerca con Google

155. Matsuzaki K, Murata M, Yoshida K, Sekimoto G, Uemura Y, Sakaida N, Kaibori M, Kamiyama Y, Nishizawa M, Fujisawa J, Okazaki K, Seki T. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor ß signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology 2007; 46(1): 48-57. Cerca con Google

156. Tsamandas AC, Thomopoulos K, Zolota V, Kourelis T, Karatzas T, Ravazoula P, Tepetes K, Petsas T, Karavias D, Karatza C, Bonicos DS, Gogos C: Potenzial role of Bcl-2 and Bax mRNA and protein expression in chronic hepatitis type B and C: a clinicopathologic study.Mod. Pathol 2003 Dec; 16(12): 1273-88. Cerca con Google

157. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649-83. Cerca con Google

158. Zhu N, Ware CF, Lai MM. Hepatitis C virus core protein enhances FADD-mediated apoptosis and suppresses TRADD signaling of tumor necrosis factor receptor. Virology 2001 May 10; 283(2):178-87 Cerca con Google

159. Tai DI, Tsai SL, Chen YM, Chuang YL, Peng CY, Sheen IS, Yeh CT, Chang KS, Huang SN, Kuo GC, Liaw YF. Activation of nuclear factor kappaB in hepatitis C virus infection: implications for pathogenesis and hepatocarcinogenesis. Hepatology 2000 Mar; 31(3): 656-64. Cerca con Google

Download statistics

Solo per lo Staff dell Archivio: Modifica questo record